A naukri.com initiative
Bioengineer
2w
341
Image Credit: Bioengineer
ITM and ILL Strengthen Partnership to Advance Manufacturing and Supply of Medical Lutetium-177 Radioisotope
- ITM and ILL strengthen their partnership to advance the manufacturing and supply of medical Lutetium-177 radioisotope for targeted cancer therapies.
- The collaboration focuses on producing non-carrier-added Lutetium-177 using ILL's high-flux neutron irradiation capabilities, crucial for radiopharmaceutical therapies in oncology.
- The neutron irradiation at ILL's High-Flux Reactor activates Ytterbium-176 to generate Lutetium-177, offering precise delivery of radiation to cancer cells while minimizing damage to healthy tissues.
- Lutetium-177's decay properties make it ideal for destroying tumor cells with beta emissions and for diagnostic monitoring with gamma emissions, enabling theranostic applications.
- ITM benefits from ILL's neutron flux for n.c.a. Lutetium-177 production, ensuring high yields and sustainability by reducing Yb-176 usage.
- The partnership aims to meet the increasing demand for quality Lutetium-177 in cancer therapies, supporting uninterrupted supply chains for clinical use.
- The collaboration bridges nuclear physics and biomedicine, emphasizing safety standards and regulatory compliance in medical isotope production for clinical applications.
- Their work extends beyond oncology, enabling the production of other essential radionuclides for diagnostics and therapies, elevating ILL's role in the global radiopharmaceutical supply chain.
- The partnership signifies a shift towards personalized medicine in healthcare, leveraging targeted radiopharmaceutical therapies like Lutetium-177 for improved patient outcomes.
- With a focus on innovation and interdisciplinary collaboration, this agreement sets the stage for next-generation cancer therapies that promise significant advancements in treatment.
Read Full Article
20 Likes
For uninterrupted reading, download the app